1. Immune-modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: a potential multi-target approach for prevention and early intervention treatment of COVID-19;Schumann;Int J Mol Sci,2020
2. Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial;Sager;Lancet Reg Health Eur,2024